Researchers studying customized cancer vaccines

Because every cancer is unique, scientists seek ways to deliver cost-effective, individualized treatment to each patient.

By Susan J. Landers — Posted Oct. 3, 2005

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

Washington -- Personalized medicine is coming full circle in cancer treatment. Individualized monoclonal antibodies had their run 30 years ago, and now vaccines that can immunize people against their own tumors hold promise.

Although customized antibodies were effective at fighting tumors, their high cost drove them from favor, and generic versions took their place.

Researchers are returning to the idea of an individualized approach to fighting cancer, but instead of making a monoclonal antibody for each person, they are exploring the possibility of teaching an individual's immune system to make its own antibodies.

Clinical trials are under way, for example, to determine the effectiveness of a cancer vaccine, and results may be forthcoming as early as next year, said Ronald Levy, MD, professor and chief of Stanford University Medical Center's oncology department.

Dr. Levy was the first to generate and use monoclonal antibodies to treat patients with lymphoma. He is now overseeing clinical trials for patients with B cell lymphoma who have been vaccinated against the receptors expressed by their own cancer cells.

"Every person will have a different cancer. This provides both a challenge and an opportunity," said Dr. Levy, who spoke at a Stanford-sponsored seminar on personalized medicine, "One Cure Does Not Fit All."

A costly process

Thirty years ago, Dr. Levy and others personalized cancer treatment by developing a separate antibody for each person, and the results were promising. "In 1982, we showed how this could work in the very first person we tried it on."

About 50 people received the treatment, but it was time-consuming and very expensive. So instead of pursuing the individualized approach, researchers formulated numerous generic antibodies.

Today, with greater understanding of genetics and of how antibodies do their work, researchers have turned, once again, to taking an individualized approach to cancer therapy.

The idea now is to find and purify a tumor cell, modify it and then inject it back into the body with the hope that an immune response will be mounted against the tumor. Patients enrolled in clinical trials first receive standard therapy, and then they are vaccinated.

Of course, developing customized vaccines will be time-consuming and expensive. And should they prove effective, demand will undoubtedly be great, Dr. Levy said. "But if you show that something works, people will get clever and develop new technology that makes it possible to deliver something in real time and in a cost-effective way."

There are additional hurdles to overcome, he noted. The drug industry is more familiar with mass producing medications than customizing them, and the health care delivery system is not attuned to customized therapies but relies on standardized care.

There is a lot to discuss, he said. "But I do think that some of the progress we are going to make in the future, particularly related to cancer, will be related to solving these problems and developing therapies that are more in tune with each individual, not just at the point of delivery, but at the point of design."

Back to top

External links

"One Cure Does Not Fit All," a seminar on personalized medicine presented Sept. 12 at Stanford University School of Medicine (link)

Back to top



Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story

Read story


American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story

Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story

Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story

Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story

Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story

Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story

Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn